Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Total Liabilities (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Total Liabilities readings, the most recent being $2.4 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 67.01% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a 67.01% decrease, with the full-year FY2025 number at $2.4 million, down 67.01% from a year prior.
  • Total Liabilities hit $2.4 million in Q4 2025 for Arcadia Biosciences, down from $3.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $28.1 million in Q2 2021 to a low of $2.4 million in Q4 2025.
  • Median Total Liabilities over the past 5 years was $8.0 million (2022), compared with a mean of $9.7 million.
  • Biggest five-year swings in Total Liabilities: crashed 70.7% in 2022 and later surged 60.31% in 2023.
  • Arcadia Biosciences' Total Liabilities stood at $12.7 million in 2021, then plummeted by 36.94% to $8.0 million in 2022, then dropped by 12.72% to $7.0 million in 2023, then rose by 4.17% to $7.3 million in 2024, then tumbled by 67.01% to $2.4 million in 2025.
  • The last three reported values for Total Liabilities were $2.4 million (Q4 2025), $3.1 million (Q3 2025), and $3.3 million (Q2 2025) per Business Quant data.